TribLIVE

| Business


 
Larger text Larger text Smaller text Smaller text | Order Photo Reprints

AstraZeneca to stay independent, 'strong'

On the Grid

From the shale fields to the cooling towers, Trib Total Media covers the energy industry in Western Pennsylvania and beyond. For the latest news and views on gas, coal, electricity and more, check out On the Grid today.

By The Associated Press
Wednesday, May 7, 2014, 12:01 a.m.
 

LONDON — AstraZeneca on Tuesday outlined plans to make sales jump during the next decade, an effort to persuade shareholders the drugmaker can do well as an independent company rather than get bought out by rival Pfizer.

In a statement, AstraZeneca said investors would share the benefits of a “strong and consistent revenue growth” in which annual sales would rise to more than $45 billion by 2023 from $25.7 billion last year.

The Britain-based company on Friday spurned Pfizer's third acquisition proposal, this time for about $106 billion. AstraZeneca PLC, the No. 8 drugmaker, called that inadequate and said the potentially lucrative “pipeline” of new drugs it is developing would be disrupted by a takeover.

AstraZeneca's revenues last year fell 6 percent, but the company said Tuesday that under its new management and strategy, it is now “repositioned for a return to growth.”

“AstraZeneca is completing its transformation and now has the right size, focus and team to deliver on one of the most exciting pipelines in the pharmaceutical industry,” Chief Executive Pascal Soriot said. “We are continuing to create significant value for shareholders from our independent strategy.”

Pfizer said last week it was considering its options. If the deal succeeds, it would be the biggest takeover in British corporate history. Many politicians fear it could mean big job cuts and a loss of stature in the country's science sector.

On Tuesday, Business Secretary Vince Cable told lawmakers he will not rule out intervening in any formal bid by Pfizer to buy AstraZeneca, although he stressed that the shareholders of both companies make the ultimate decision.

“We see the future of the U.K. as a knowledge economy, not as a tax haven,” he said, referring to concerns that Pfizer could benefit from tax advantages should it acquire AstraZeneca.

 

 
 


Show commenting policy

Most-Read Business Headlines

  1. PUC approves Columbia Gas pipeline extensions program for homeowners
  2. Education Management removes itself from Nasdaq listing
  3. Mortgage rate slide’s impact could be minimal
  4. Amid struggles, top fiscal executive to leave EDMC
  5. Highmark seeks double-digit increase for more benefits, heavy use
  6. Stocks jump on strong earnings, led by 3M, Caterpillar
  7. Energy Spotlight: Steve Anthos
  8. EQT Corp. boosts profits despite lower gas prices
  9. Toy sellers to enhance marketing as holidays approach
  10. Rule to close coal royalty loophole
  11. Chevron puts $20M into educating, training Appalachian workers
Subscribe today! Click here for our subscription offers.